MedTrace Logo

Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS

NCT03520517 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2022-10-06

No results posted yet for this study

Summary

Phase 1, open-label study of BHV-0223 in ALS.

Conditions

Interventions

DRUG

BHV-0223

BHV-0223, 40 mg BID

Sponsors & Collaborators

  • Cognitive Research Corporation

    collaborator INDUSTRY

  • Biohaven Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-02
Primary Completion
2018-10-08
Completion
2018-10-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03520517 on ClinicalTrials.gov